Biotech Breakthroughs: A Recap of 2023
By: Mukesh Yadav In 2023, a significant milestone was reached in Alzheimer’s disease treatment with the FDA’s approval of LEQEMBI (lecanemab-irmb). Developed by Eisai Co., Ltd. and Biogen Inc., this treatment showed efficacy in slowing cognitive decline in early-stage AD patients, marking the first of its kind. Additionally, biotech advancements included the development of Alzheimer’s…
